# Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors

> **NCT07656090** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 19 (estimated)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** Oncolytic Virus injection(IDOV-Immune)

## Key facts

- **NCT ID:** NCT07656090
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-12-18
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07656090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07656090, "Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07656090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*